CVS/pharmacy: Flu shot clinics will run through Oct. 22
WOONSOCKET, R.I. CVS/pharmacy announced on Thursday that its seasonal flu shot clinics will run through Oct. 22, in light of manufacturer delays in delivery of the vaccine affecting all healthcare providers. However, MinuteClinic will continue to administer seasonal flu vaccines at its 500 locations in 25 states throughout the flu season, with the supply being replenished as frequently as possible.
“We’re very pleased that so many of our customers have heeded the message to get a seasonal flu shot this year either at CVS/pharmacy or at MinuteClinic in rates far exceeding last year and even our own expectations for this flu season,” stated Troyen Brennan, M.D., chief medical officer for CVS Caremark.
Brennan added that the next step for patients this flu season is to get the H1N1 vaccine, which the company expects to offer once it is available.
Abbott reports Q3 results
ABBOTT PARK, Ill. Drug maker Abbott reported strong sales in its third-quarter 2009 earnings report Wednesday.
The company reported an increase of 8.4% in global sales, which remained at 3.5% when factoring in the rise in the value of the dollar. Excluding the dollar’s rise, pharmaceutical sales were 3.9%, but dipped into the red, to -1.6%, when including foreign exchange rates. Nutritional and medical products had much stronger sales – 11.1% and 9.8%, respectively – when the dollar’s value was included.
“Abbott is performing well, generating higher-than-expected earnings growth in the fourth quarter,” Abbott chairman and CEO Miles White said in a statement. “During the quarter, we announced several acquisitions that support our long-term growth strategy. These acquisitions add to our diverse mix of global businesses, with new technologies, established products and emerging market infrastructure that will help us deliver sustainable industry-leading growth.”
Mylan, Pfizer settle drug dispute
PITTSBURGH Generic drug manufacturer Mylan and pharmaceutical giant Pfizer have settled a dispute over Mylan’s attempt to manufacture a generic version of an antifungal drug.
Mylan announced Wednesday that it had entered a license agreement with Pfizer concerning Mylan subsidiary Matrix Labs’ voriconazole tablets in the 50-mg and 200-mg strengths, a generic version of Pfizer’s Vfend. Matrix had filed a regulatory approval application with the Food and Drug Administration; as the first company to file the application, Mylan will have the right to market its version in direct competition with Pfizer’s product for six months once the patent expires. Under the agreement, Mylan will have the right to market voriconazole tablets in the U.S. in first quarter 2011.
Vfend, used to treat yeast and other fungal infections, had sales of $164 million during the 12-month period ending June 30, according to IMS Health data.